(R)-2-(((3-Methyl-4-nitropyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole

Catalog No. :
ACICKO432
CAS No. :
853950-77-3
Molecular Formula :
C14H12N4O3S
Molecular Weight :
316.34

IUPAC Name:(R)-2-(((3-methyl-4-nitropyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole

(R)-2-(((3-Methyl-4-nitropyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(R)-2-(((3-Methyl-4-nitropyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
IUPAC Name(R)-2-(((3-methyl-4-nitropyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
Molecular FormulaC14H12N4O3S
Molecular Weight316.34
SMILESO=[S@@](C1=NC2=CC=CC=C2N1)CC3=NC=CC([N+]([O-])=O)=C3C
InChI KeyPSPWSLJRXBXEMQ-JOCHJYFZSA-N
Synonym2-[(R)-(3-methyl-4-nitropyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole;1H-Benzimidazole, 2-[(R)-[(3-methyl-4-nitro-2-pyridinyl)methyl]sulfinyl]-;(R)-2-(((3-methyl-4-nitropyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole;Dexlansoprazole Nitro SulphoxideQ: What is Dexlansoprazole Nitro Sulphoxide Q: What is the CAS Number of Dexlansoprazole Nitro Sulphoxide;(R)-2-{[(3-methyl-4-nitropyridine-2-yl)methyl]sulfinyl}-1H-benzimidazole
CAS No.853950-77-3

Synthetic Route by SureRoute

1. ACICKO432 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACICKO432 route product structure diagram
    ACICKO432853950-77-3
Inquiry

2. ACICKO432 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACICKO432 route product structure diagram
    ACICKO432853950-77-3
Inquiry

Comments (0)